LTR PHARMA LIMITED — Director's Dealing 2024

Dec 8, 2024

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity LTR Pharma Limited (ASX:LTP) ABN 42 103 087 449

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lee Rodne
Date of last notice	13 December 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	(1) Direct (2) Indirect (3) Indirect (4) Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	(1) N/A (2) LTR Medical Pty Ltd (3) LTR Consulting Pty Ltd (4) Trexapharm Inc
Date of change	(1) 2 December 2024 (2) N/A (3) N/A (4) N/A
No. of securities held prior to change	(1) 1,129,641 Fully Paid Ordinary Shares 1,000,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 (2) 46,373,750 Fully Paid Ordinary Shares (3) 982,143 Fully Paid Ordinary Shares (4) 4,188,000 Fully Paid Ordinary Shares
Class	(1) Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) N/A (3) N/A (4) N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired	(1) 100,000 (2) N/A (3) N/A (4) N/A
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	No cash consideration
No. of securities held after change	(1) 1,129,641 Fully Paid Ordinary Shares 1,000,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) 46,373,750 Fully Paid Ordinary Shares (3) 982,143 Fully Paid Ordinary Shares (4) 4,188,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Grant of 100,000 unlisted options in accordance with a resolution of shareholders at the 2024 Annual General Meeting on the terms and conditions described in the Notice of Annual General Meeting and the Explanatory Notes whichaccompanied the Notice.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity LTR Pharma Limited (ASX:LTP) ABN 42 103 087 449

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Julian Chick
Date of last notice	13 December 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	(1) Direct (2) Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	(1) N/A (2) LTR Medical Pty Ltd
Date of change	(1) 2 December 2024 (2) N/A
No. of securities held prior to change	(1) 808,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 (2) 46,373,750 FullyPaid OrdinaryShares
Class	(1) Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) N/A
Number acquired	(1) 100,000 (2) N/A
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	No cash consideration

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	(1) 808,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) 46,373,750 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Grant of 100,000 unlisted options in accordance with a resolution of shareholders at the 2024 Annual General Meeting on the terms and conditions described in the Notice of Annual General Meeting and the Explanatory Notes whichaccompanied the Notice.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

If prior written clearance was provided, on what date was this provided?

N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity LTR Pharma Limited (ASX:LTP) ABN 42 103 087 449

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maja McGuire
Date of last notice	13 December 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	(1) Direct (2) Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	(1) N/A (2) Maja McGuire ATF Scaraf Trust
Date of change	(1) 2 December 2024 (2) N/A
No. of securities held prior to change	(1) N/A (2) 235,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22per option expiring31 October 2028
Class	(1) Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) N/A
Number acquired	(1) 100,000 (2) N/A
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	No cash consideration

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	(1) 100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) 235,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Grant of 100,000 unlisted options in accordance with a resolution of shareholders at the 2024 Annual General Meeting on the terms and conditions described in the Notice of Annual General Meeting and the Explanatory Notes whichaccompanied the Notice.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

If prior written clearance was provided, on what date was this provided?

N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3